HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.8%

Neg 0% Neu 91.8% Pos 0%

HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $55 price target.